Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
Inhye E. Ahn(Dana-Farber Cancer Institute), Matthew S. Davids(Dana-Farber Cancer Institute), Svitlana Tyekucheva(Harvard University), Jennifer R. Brown(Dana-Farber Cancer Institute), Jon Arnason(Beth Israel Deaconess Medical Center), Ronald W. Takvorian(Massachusetts General Hospital), Josie Montegaard(Dana-Farber Cancer Institute), Ephraim P. Hochberg(Massachusetts General Hospital), Caron A. Jacobson(Dana-Farber Cancer Institute), Leyla Shune(University of Kansas Medical Center), Danielle M. Brander(Duke University), Robert Black(Dana-Farber Cancer Institute), Philippe Armand(Harvard University), Mohammad Omaira(West Michigan Cancer Center), Heather A. Walker(Dana-Farber Cancer Institute), Yinglu Zhou(Dana-Farber Cancer Institute), Ann S. LaCasce(Otsuka (Japan)), Alvaro J. Alencar(University of Miami), Jennifer L. Crombie(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Jeremy S. Abramson(Massachusetts General Hospital), Samuel Y. Ng(National Cancer Institute), Yue Ren(Dana-Farber Cancer Institute)
Cited by 12
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k